These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluation. Graham TH; Liu W; Verras A; Sebhat IK; Xiong Y; Bleasby K; Bhatt UR; Chen Q; Garcia-Calvo M; Geissler WM; Gorski JN; He H; Lassman ME; Lisnock J; Li X; Shen Z; Tong X; Tung EC; Wiltsie J; Xiao J; Xie D; Xu S; Hale JJ; Pinto S; Shen DM Bioorg Med Chem Lett; 2012 Apr; 22(8):2811-7. PubMed ID: 22444683 [TBL] [Abstract][Full Text] [Related]
7. The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors. Graham TH; Shen HC; Liu W; Xiong Y; Verras A; Bleasby K; Bhatt UR; Chabin RM; Chen D; Chen Q; Garcia-Calvo M; Geissler WM; He H; Lassman ME; Shen Z; Tong X; Tung EC; Xie D; Xu S; Colletti SL; Tata JR; Hale JJ; Pinto S; Shen DM Bioorg Med Chem Lett; 2012 Jan; 22(1):658-65. PubMed ID: 22079761 [TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors. Ramurthy S; Aikawa M; Amiri P; Costales A; Hashash A; Jansen JM; Lin S; Ma S; Renhowe PA; Shafer CM; Subramanian S; Sung L; Verhagen J Bioorg Med Chem Lett; 2011 Jun; 21(11):3286-9. PubMed ID: 21543226 [TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors. Debenham JS; Graham TH; Verras A; Zhang Y; Clements MJ; Kuethe JT; Madsen-Duggan C; Liu W; Bhatt UR; Chen D; Chen Q; Garcia-Calvo M; Geissler WM; He H; Li X; Lisnock J; Shen Z; Tong X; Tung EC; Wiltsie J; Xu S; Hale JJ; Pinto S; Shen DM Bioorg Med Chem Lett; 2013 Dec; 23(23):6228-33. PubMed ID: 24157366 [TBL] [Abstract][Full Text] [Related]
10. Pyrazoles as non-classical bioisosteres in prolylcarboxypeptidase (PrCP) inhibitors. Graham TH; Shu M; Verras A; Chen Q; Garcia-Calvo M; Li X; Lisnock J; Tong X; Tung EC; Wiltsie J; Hale JJ; Pinto S; Shen DM Bioorg Med Chem Lett; 2014 Apr; 24(7):1657-60. PubMed ID: 24636945 [TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors. Ramurthy S; Costales A; Jansen JM; Levine B; Renhowe PA; Shafer CM; Subramanian S Bioorg Med Chem Lett; 2012 Feb; 22(4):1678-81. PubMed ID: 22264479 [TBL] [Abstract][Full Text] [Related]
12. Arylamine based cathepsin K inhibitors: investigating P3 heterocyclic substituents. Shinozuka T; Shimada K; Matsui S; Yamane T; Ama M; Fukuda T; Taki M; Takeda Y; Otsuka E; Yamato M; Naito S Bioorg Med Chem; 2006 Oct; 14(20):6807-19. PubMed ID: 16829073 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors. Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001 [TBL] [Abstract][Full Text] [Related]
14. Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists. Wang L; Hubert JA; Lee SJ; Pan J; Qian S; Reitman ML; Strack AM; Weingarth DT; MacNeil DJ; Weber AE; Edmondson SD Bioorg Med Chem Lett; 2011 May; 21(10):2911-5. PubMed ID: 21493064 [TBL] [Abstract][Full Text] [Related]
15. Heteroalicyclic carboxamidines as inhibitors of inducible nitric oxide synthase; the identification of (2R)-2-pyrrolidinecarboxamidine as a potent and selective haem-co-ordinating inhibitor. Young RJ; Alderton W; Angell AD; Beswick PJ; Brown D; Chambers CL; Crowe MC; Dawson J; Hamlett CC; Hodgson ST; Kleanthous S; Knowles RG; Russell LJ; Stocker R; Woolven JM Bioorg Med Chem Lett; 2011 May; 21(10):3037-40. PubMed ID: 21482467 [TBL] [Abstract][Full Text] [Related]